| Literature DB >> 21956522 |
Lingjian Zhu1, Pengfei Cheng, Ning Lei, Jianzhong Yao, Chunquan Sheng, Chunlin Zhuang, Wei Guo, Wenfeng Liu, Yongqiang Zhang, Guoqiang Dong, Shengzhang Wang, Zhenyuan Miao, Wannian Zhang.
Abstract
Homocamptothecin (hCPT) is a camptothecin (CPT) homologue with the insertion of a methylene (CH₂) spacer between the alcohol moiety and carbonyl group of the classical six-membered α-hydroxylactone ring. This modification provides higher lactone stability and did not impair its activity against topoisomerase I (Topo I), but rather appears to improve it compared to CPT. In an attempt to improve the antitumor activity of homocamptothecins, a series of novel hCPT derivatives conjugating with dihydropyrimidine (DHPM) derivatives was designed and synthesized based on a synthetic route which couples 7-formylhomocamptothecin with different dihydropyrimidine derivates. Most of the synthesized compounds exhibited good antiproliferative activity on tumor cell lines A549, MDA-MB-435 and HCT116. Furthermore, this class of compounds showed superior Topo I inhibition activity comparable to or higher than CPT. 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21956522 DOI: 10.1002/ardp.201000402
Source DB: PubMed Journal: Arch Pharm (Weinheim) ISSN: 0365-6233 Impact factor: 3.751